EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 38 / No 11 (Novembre 2022) Med Sci (Paris), 38 11 (2022) 963-965 References
Issue
Med Sci (Paris)
Volume 38, Number 11, Novembre 2022
Nos jeunes pousses ont du talent !
Page(s) 963 - 965
Section Partenariat médecine/sciences - Écoles doctorales - Masters
DOI https://doi.org/10.1051/medsci/2022143
Published online 30 November 2022
  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians 2021; 71 : 209–49. [CrossRef] [PubMed] [Google Scholar]
  2. Doroshow DB, Sanmamed MF, Hastings K, et al. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clin Cancer Res 2019 ; 25 : 4592–4602. [CrossRef] [PubMed] [Google Scholar]
  3. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019 ; 20 : 924–937. [CrossRef] [PubMed] [Google Scholar]
  4. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018 ; 379 : 2040–2051. [CrossRef] [PubMed] [Google Scholar]
  5. Lei Q, Wang D, Sun K, et al. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. Front Cell Dev Biol 2020; 8. [PubMed] [Google Scholar]
  6. Zhao Y, Liu Y, Li S, et al. Role of lung and gut microbiota on lung cancer pathogenesis. J Cancer Res Clin Oncol 2021; 147 : 2177–86. [CrossRef] [PubMed] [Google Scholar]
  7. Liu X, Cheng Y, Zang D, et al. The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy. Front Oncol 2021; 11. [Google Scholar]
  8. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018 ; 359 : 91–97. [Google Scholar]
  9. Elkrief A, Derosa L, Zitvogel L, et al. The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes 2019 ; 10 : 424–428. [CrossRef] [PubMed] [Google Scholar]
  10. Vétizou M, Daillère R, Zitvogel L. Microbiote intestinal et réponses aux thérapies anti-tumorales. Med Sci (Paris) 2016 ; 32 : 974–982. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  11. He D, Li X, An R, et al. Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota. Oncol Ther 2021; 9 : 647–57. [CrossRef] [PubMed] [Google Scholar]
  12. Sannicolo S, Giaj Levra M, Le Gouellec A, et al. Identification of a predictive metabolic signature of response to immune checkpoint inhibitors in non-small cell lung cancer: METABO-ICI clinical study protocol. Respir Med Res 2021; 80 : 100845. [PubMed] [Google Scholar]
  13. Hindson J. FMT for immunotherapy-refractory melanoma. Nat Rev Gastroenterol Hepatol 2021; 18 : 82. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.